Tm Bioscience Licenses Intellectual Property From Abbott
News Oct 04, 2005
Tm Bioscience Corporation has announced that it has concluded a license agreement with Abbott for certain intellectual property in the areas of, among others, human and pathogen genotyping.
The non-exclusive license is worldwide, expires co-terminously with the associated patents and covers Tm's current and future products in all fields of use.
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018